The efficacy and tolerability of two novel H 1/H 3 receptor antagonists in seasonal allergic rhinitis

International Archives of Allergy and Immunology

Volumn 158, Issue 1, 2012, Pages 84-98

  Daley Yates, Peter ^a   Ambery, Claire ^a   Sweeney, Lisa ^a   Watson, Joanna ^a   Oliver, Amanda ^a   McQuade, Barbara ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Allergen chamber; H 1 H 3; H 3 antagonist; Seasonal allergic rhinitis

Indexed keywords

ALLERGEN; CETIRIZINE; GSK 1004723; GSK 835726; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BRONCHITIS; COUGHING; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; NOSE AIRFLOW; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SUSPENSION; SYMPTOM; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INTRANASAL; ANTI-ALLERGIC AGENTS; CETIRIZINE; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HISTAMINE H1 ANTAGONISTS; HISTAMINE H3 ANTAGONISTS; HUMANS; MALE; NAPHTHALENES; NASAL OBSTRUCTION; PHTHALAZINES; PIPERIDINES; RHINITIS, ALLERGIC, SEASONAL;

EID: 84855182414     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000329738     Document Type: Review

References (29)

1. Naclerio RM: Allergic rhinitis. N Engl J Med 1991; 325: 860-869.
2. Naclerio R: Clinical manifestations of the release of histamine and other inflammatory mediators. J Allergy Clin Immunol 1999; 103:S382-S385. (Pubitemid 29136280)
3. Doyle WJ, Boehm S, Skoner DP: Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy. J Allergy Clin Immunol 1990; 86: 924-935.
4. Howarth PH, Salagean M, Dokic D: Allergic rhinitis: Not purely a histamine-related disease. Allergy 2000; 55:(suppl 64)7-16. (Pubitemid 32095164)
5. Kirkegaard J, Secher C, Borum P, Mygind N: Inhibition of histamine-induced nasal symptoms by the H1 antihistamine chlorpheniramine maleate: Demonstration of topical effect. Br J Dis Chest 1983; 77: 113-122. (Pubitemid 13117363)
6. Hilberg O, Grymer LF, Pedersen OF: Nasal histamine challenge in nonallergic and allergic subjects evaluated by acoustic rhinometry. Allergy 1995; 50: 166-173.
7. Babe KS, Serafin WE: Histamine bradykinin and their antagonists; in Hardman G, Limbind LE (eds): Goodman and Gilman, The Pharmacological Basis of Therapeutics, ed 9. New York, McGrawHill, 1996, pp 581-600.
8. Prenner BM, Schenkel E: Allergic rhinitis: Treatment based on patient profiles. Am J Med 2006; 119: 230-237. (Pubitemid 43255061)
9. Spector S: Ideal pharmacotherapy for allergic rhinitis. J Allergy Clin Immunol 1999; 103:S386-S387. (Pubitemid 29136281)
10. Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S, Ryan D, Walker SM, Clark AT, Dixon TA, Jolles SRA, Siddique N, Cullinan P, Howarth PH, Nasser SM: BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2009;38:19-42. (Pubitemid 350233401)
11. McLeod RL, Mingo GG, Herczku C, De-Gennaro-Culver F, Kreutner W, Egan RW, Hey JA: Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am J Rhinol 1999; 13: 391-399.
12. Arrang JM, Garbarg M, Schwartz JC: Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302: 832-837. (Pubitemid 13125123)
13. Koss MC, Hey JA: Prejunctional inhibition of sympathetically evoked pupillary dilation in cats by activation of histamine H3 receptors. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 141-145. (Pubitemid 23251332)
14. Ohkubo T, Shibata M, Inoue M, Kaya H, Takahashi H: Regulation of substance P release mediated via prejunctional histamine H3 receptors. Eur J Pharmacol 1995; 273: 83-88.
15. Ichinose M, Barnes PJ. Inhibitory histamine H3-receptors on cholinergic nerves in human airways. Eur J Pharmacol 1989; 163: 383-386. (Pubitemid 19126308)
16. Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R, Haas HL: International union of pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 1997; 49: 253-278. (Pubitemid 27414915)
17. Nakaya M, Takeuchi N, Kondo K: Immunohistochemical localization of histamine receptor subtypes in human inferior turbinates. Ann Otol Rhinol Laryngol 2004; 113: 552-557. (Pubitemid 38902552)
18. Yokota E, Kuyama S, Sugimoto Y, Ogawa M, Kamei C: Participation of Histamine H3 Receptors in Experimental Allergic Rhinitis of Mice. J Pharmacol Sci 2008; 108: 206-211.
19. McLeod RL, Egan RW, Cuss FM, Bolser DC, Hey JA: New drugs for Asthma, Allergy and COPD. Prog Respir Res 2001; 31: 133-136.
20. Taylor-Clark T, Sodha R, Warner B, Foreman J: Histamine receptors that influence blockage of the normal human nasal airway. Br J Pharmacol 2005; 144: 867-874. (Pubitemid 40516126)
21. Varty LM, Gustafson E, Laverty M, Hey JA: Activation of histamine H3 receptors in human nasal mucosa inhibits sympathetic vasoconstriction. Eur J Pharmacol 2004; 484: 83-89. (Pubitemid 38068537)
22. Procopiou PA, Browning C, Buckley JM, Clark KL, Fechner L, Gore PM, Hancock AP, Hodgson ST, Holmes DS, Kranz M, Looker BE, Morriss KML, Parton DL, Russell LJ, Slack RJ, Sollis SL, Vile S, Watts CJ: The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis. J Med Chem 2011;54: 2183-2195.
23. Romero FA, Allan RJ, Phillips PG, Hutchinson JM, Misfeldt JM, Casale TB: The Effects Of An H3 Receptor Antagonist In A Nasal Allergen Challenge Model. JACI 2010; 125(issue 2):supplement:AB191.
24. Slack RJ, Russell LJ, Hall DA, Luttmann MA, Ford AJ, Saunders KA, Hodgson ST, Connor HE, Browning C, Clark KL: Pharmacological characterisation of GSK1004723, a novel, long acting antagonist at histamine H1 and H3 receptors. Br J Pharmacol 2011, in press.
25. Ford A, Browning C, Russell L, Saunders K, Hall D, Morrison V, Changani K, Hodgson S, Clark K: Preclincal pharmacology of the novel oral dual histamine H1 and H3 receptor antagonist GSK835726. Allergy 2009; 64(suppl 90):134.
26. Norman P: New H1/H3 antagonists for treating allergic rhinitis. Expert Opin Ther 2011;21:425-429.
27. Hohlfeld JM, Holland-Letz T, Larbig M, Lavae-Mokhtari M, Wierenga E, Kapsenberg M, van Ree R, Krug N, Bufe A: Diagnostic value of outcome measures following allergen exposure in an environmental challenge chamber compared with natural conditions. Clin Exp Allergy 2010;40:998-1006.
28. Badorrek P, Dick M, Schauerte A, Hecker H, Murdoch R, Luettig B, Hohlfeld JM, Krug N: A combination of cetirizine and pseudoephedrine has therapeutic benefits when compared to single drug treatment in allergic rhinitis. Int J Clin Pharmacol Ther 2009;47:71-77.
29. Daley-Yates PT, Stone S, Allen A, Lambert J: Nasal absorption of fluticasone propionate: Influence of formulation, dissolution and breath holding; in Dalby RN, Byron PR, Peart J, Suman JD (eds): Respiratory Drug Deliv -ery Europe. Richmond, Virginia Commonwealth University, 2007, vol 1, pp 271-274.